Literature DB >> 18632847

Cinacalcet reduces the set point of the PTH-calcium curve.

Casimiro Valle1, Mariano Rodriguez, Rafael Santamaría, Yolanda Almaden, Maria E Rodriguez, Sagrario Cañadillas, Alejandro Martin-Malo, Pedro Aljama.   

Abstract

The calcimimetic cinacalcet increases the sensitivity of the parathyroid calcium-sensing receptor to calcium and therefore should produce a decrease in the set point of the parathyroid hormone (PTH)-calcium curve. For investigation of this hypothesis, nine long-term hemodialysis patients with secondary hyperparathyroidism were given cinacalcet for 2 mo, the dosage was titrated per a protocol based on intact PTH and plasma calcium concentrations. Dialysis against low- and high-calcium (0.75 and 1.75 mM) dialysate was used to generate curves describing the relationship between PTH and calcium. Compared with precinacalcet levels, cinacalcet significantly reduced mean serum calcium, intact PTH and whole PTH (wPTH; all P < 0.001). The set points for PTH-calcium curves were significantly reduced, and both maximum and minimum levels of PTH (intact and whole) were significantly decreased. The calcium-mediated inhibition of PTH secretion was more marked after cinacalcet treatment. In addition, cinacalcet shifted the inverse sigmoidal curve of wPTH/non-wPTH ratio versus calcium to the left (i.e., less calcium was required to reduce the wPTH/non-wPTH ratio). In conclusion, cinacalcet increases the sensitivity of the parathyroids to calcium, causing a marked reduction in the set point of the PTH-calcium curve, in hemodialysis patients with secondary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632847      PMCID: PMC2588095          DOI: 10.1681/ASN.2007121320

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  34 in total

1.  The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients.

Authors:  M Pahl; A Jara; J Bover; M Rodriguez; A J Felsenfeld
Journal:  Kidney Int       Date:  1996-01       Impact factor: 10.612

2.  Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values.

Authors:  J H Brossard; M Cloutier; L Roy; R Lepage; M Gascon-Barré; P D'Amour
Journal:  J Clin Endocrinol Metab       Date:  1996-11       Impact factor: 5.958

3.  Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue.

Authors:  E M Brown
Journal:  J Clin Endocrinol Metab       Date:  1983-03       Impact factor: 5.958

4.  Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism.

Authors:  J Gogusev; P Duchambon; B Hory; M Giovannini; Y Goureau; E Sarfati; T B Drüeke
Journal:  Kidney Int       Date:  1997-01       Impact factor: 10.612

5.  Evidence for adaptation of the entire PTH-calcium curve to sustained changes in the serum calcium in haemodialysis patients.

Authors:  M J Borrego; A J Felsenfeld; A Martin-Malo; Y Almaden; M T Concepción; P Aljama; M Rodriguez
Journal:  Nephrol Dial Transplant       Date:  1997-03       Impact factor: 5.992

6.  The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients.

Authors:  M Rodriguez; A J Felsenfeld; C Williams; J A Pederson; F Llach
Journal:  J Am Soc Nephrol       Date:  1991-11       Impact factor: 10.121

7.  Parathyroid gland function in chronic renal failure.

Authors:  A J Felsenfeld; F Llach
Journal:  Kidney Int       Date:  1993-04       Impact factor: 10.612

8.  Calcium-regulated parathyroid hormone release in patients with mild or advanced secondary hyperparathyroidism.

Authors:  W G Goodman; T Belin; B Gales; H Juppner; G V Segre; I B Salusky
Journal:  Kidney Int       Date:  1995-11       Impact factor: 10.612

9.  Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism.

Authors:  J A Ramirez; W G Goodman; T R Belin; B Gales; G V Segre; I B Salusky
Journal:  Am J Physiol       Date:  1994-12

10.  Relationship between the concentration and rate of change of calcium and serum intact parathyroid hormone levels in normal humans.

Authors:  G A Brent; M S LeBoff; E W Seely; P R Conlin; E M Brown
Journal:  J Clin Endocrinol Metab       Date:  1988-11       Impact factor: 5.958

View more
  13 in total

1.  Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication.

Authors:  Vincenzo Marotta; Carolina Di Somma; Manila Rubino; Concetta Sciammarella; Michela Del Prete; Francesca Marciello; Valeria Ramundo; Luisa Circelli; Pasqualina Buonomano; Roberta Modica; Mario Vitale; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2014-08-15       Impact factor: 3.633

Review 2.  Old and New Drugs for the Management of Bone Disorders in CKD.

Authors:  Hirotaka Komaba; Markus Ketteler; John Cunningham; Masafumi Fukagawa
Journal:  Calcif Tissue Int       Date:  2021-01-02       Impact factor: 4.333

Review 3.  The regulation of parathyroid hormone secretion and synthesis.

Authors:  Rajiv Kumar; James R Thompson
Journal:  J Am Soc Nephrol       Date:  2010-12-16       Impact factor: 10.121

Review 4.  Rationale to reduce calcium intake in adult patients with chronic kidney disease.

Authors:  Sharon M Moe
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-07       Impact factor: 2.894

Review 5.  Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies.

Authors:  Mariano Rodríguez Portillo; María E Rodríguez-Ortiz
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

Review 6.  Management of secondary hyperparathyroidism in the elderly patient with chronic kidney disease.

Authors:  Mario Cozzolino; Maurizio Gallieni; Sabina Pasho; Giuditta Fallabrino; Paola Ciceri; Elisa Maria Volpi; Laura Olivi; Diego Brancaccio
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 7.  Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions.

Authors:  Tejas V Patel; Ajay K Singh
Journal:  Semin Nephrol       Date:  2009-03       Impact factor: 5.299

8.  Reversible bone pain and symmetric bone scan uptake in a dialysis patient treated with cinacalcet: a case report.

Authors:  Oliver Lenz; Rhea Sancassani; Carla Bottino; Alessia Fornoni
Journal:  J Med Case Rep       Date:  2010-06-24

9.  Cinacalcet: the chemical parathyroidectomy?

Authors:  Antonio Bellasi; Mario Cozzolino
Journal:  Clin Kidney J       Date:  2013-06

10.  Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy.

Authors:  Ryo Koda; Junichiro James Kazama; Koji Matsuo; Kazuko Kawamura; Suguru Yamamoto; Minako Wakasugi; Tetsuro Takeda; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2014-11-11       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.